Skip to main content
Premium Trial:

Request an Annual Quote

SpeeDx Raises Additional $15M

NEW YORK — Australian diagnostics firm SpeeDx said on Tuesday that it has raised $15 million in new Series B funding.

The investment was made by Northpond Ventures, which last year invested $20 million in SpeeDx. 

The firm will use the additional funds to support its product and services pipeline, SpeeDx CFO Bhavin Raval said in a statement.

SpeeDx recently launched its flagship ResistancePlus MG FleXible test for the sexually transmitted disease Mycoplasma genitalium, as well as markers associated with azithromycin resistance. The test is exclusively distributed by Cepheid for use on its GeneXpert System and is currently available in Australia, New Zealand, and parts of Europe including the UK.

SpeeDx said it is currently finalizing clinical trials of ResistancePlus MG in the US and is preparing to begin US-based clinical studies of the ResistancePlus GC test for determining the susceptibility of gonorrhea infections to ciprofloxacin. The company also recently partnered with Laboratory Corporation of America to codevelop diagnostic assays for women's health and infectious disease indications.

The Scan

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.

Australian Survey Points to Public Support for Genetic Risk Disclosure in Relatives of At-Risk Individuals

A survey in the European Journal of Human Genetics suggests most adult Australians are in favor of finding out if a relative tests positive for a medically actionable genetic variant.

Study Links Evolution of Stony Coral Skeleton to Bicarbonate Transporter Gene

A PNAS paper focuses on a skeleton-related bicarbonate transporter gene introduced to stony coral ancestors by tandem duplication.

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.